Rising prevalence of anaphylaxis and increasing healthcare spending
are some of the key drivers for the global market growth. Additionally,
emerging biologic drug therapies, minimized needle-stick injuries and growing
aging population also support the growth of the global market.
In terms of therapeutic application, the auto-injectors market is
segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis and
others. The other applications include migraine, psoriasis and diabetes. Among
the therapeutic application, the anaphylaxis segmented contributed to almost
88% of the overall market for auto-injectors in 2016. Some of the major factors
driving the growth of this application include, increasing prevalence of
anaphylaxis globally and rising awareness about the auto-injectors for treating
various allergies effectively.
The increasing prevalence of these various chronic diseases has led to
rising government and non-government initiatives which in turn has led to
increased healthcare spending globally. Rise in affordability and accessibility
of advanced healthcare solutions has further led to high healthcare spending.
According to the World Health Organization (WHO), the total healthcare
expenditure has increased globally, leading to high healthcare infrastructure
and increased use of advanced healthcare devices such as pens, auto-injectors,
wearable injectors for self-medication by patients suffering from anaphylaxis,
diabetes, multiple sclerosis, migraine and rheumatoid arthritis. The demand for
self-injection devices has been increasing with the increasing prevalence of
such diseases which require daily or weekly doses and hence, supporting the
growth of the global auto-injectors market.
The major players in the auto-injectors market are launching new
products to improve their position in the market. For instance, in December
2016, Mylan N V launched generic Cerebyx injection for the treatment of several
different type of seizures. The product is part of Mylan's growing global
portfolio of more than 450 injectable products, which includes liquid,
lyophilized and dry-powder formulations delivered in a range of mechanisms including
ampoules, vials, ready-to-use bags and pre-filled syringes.
Some of the key players operating in the auto-injectors market include Mylan N.V., Antares Pharma Inc., Becton, Dickinson & Co., Eli Lilly and Company, Pfizer, Inc., Bayer AG, Novartis International AG, Bristol-Myer Squibb, Novartis AG, Amgen Inc. and Biogen Inc.
Share This
Email
Facebook
Twitter
Read Request
My Library
Subscribe
Flag Writing
